News | November 17, 2010

Lunch Symposium to Highlight Medical Simulation Technology

November 17, 2010 – A lunch symposium detailing the evidence for simulation in medical training and other fields will be sponsored by W.L. Gore and Associates at the VEITHsymposium. The EVEResT (European Virtual Reality Endovascular Research Team) lunch symposium will take place Nov. 19 from 12:00 to 1:00 p.m. in the Gramercy A room, second floor.

Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.

Rapid advances in technology and a demand for increased patient safety have led to a growing interest in simulation as a training tool for complex procedures. As a result, some of the world’s leading vascular surgeons and radiologists are participating in the event.

It is chaired by Nicholas Cheshire, M.D., professor of vascular surgery, head of circulation sciences and renal medicine, Imperial College Healthcare, Campus St. Mary’s Hospital, London; Mario Lachat, M.D., head of cardiovascular surgery, University Hospital, Zurich, Switzerland; and Isabelle van Herzeele, M.D., Ph.D, consultant at the department of thoracic and vascular surgery at Ghent University Hospital, Belgium and Honorary Fellow at the department of biosurgery and surgical technology NHS Trust, Campus St. Mary's Hospital, London.

The group was founded involving three academic centers and the three specialties (cardiology, radiology, vascular surgery) involved in endovascular treatments of vascular diseases. This collaboration is intended to inspire other academic centers, professional societies and medical device companies to work together and develop a standardized approach for endovascular training and assessment.


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now